Free Trial Information
BioCentury | Jul 1, 2002
Finance

Cash watch

...$7.5 0.3 Genomic Solutions $25.1 $7.2 0.3 BioTime $3.3 $1.0 0.3 Heska $13.4 $4.2 0.3 Enchira...
Read More
BioCentury | May 13, 2002
Company News

Enchira genomics, proteomics news

...proteins that block cancer-related tyrosine kinase targets. The company said it is selling its assets. Enchira Biotechnology Corp....
Read More
BioCentury | Apr 15, 2002
Company News

Dyax, Enchira deal

...non-exclusively licensed its phage display technology to cancer company ENBC. Dyax Corp. (DYAX), Cambridge, Mass. Enchira Biotechnology Corp....
Read More
BioCentury | Jan 22, 2002
Company News

Enchira scientific advisory board update

Enchira Biotechnology Corp. (ENBC), The Woodlands, Texas Business: Genomics, Proteomics Appointed: John Smyth, professor of medical oncology at the University of Edinburgh; James Swartz, professor of chemical engineering at Stanford University; and Adrian Lee, assistant...
Read More
BioCentury | Dec 3, 2001
Clinical News

Template-based recombination methods regulatory update

...the patent covers the Rachitt technology, to which MAXY obtained exclusive ownership through arbitration with Enchira Biotechnology Corp....
Read More
BioCentury | Nov 19, 2001
Company News

Enchira scientific advisory board update

Enchira Biotechnology Corp. (ENBC), The Woodlands, Texas Business: Genomics, Proteomics Appointed: Lee Ellis, professor of surgical oncology and cancer biology at the University of Texas M.D. Anderson Cancer Center WIR Staff cancer...
Read More
BioCentury | Nov 12, 2001
Company News

Enchira, Maxygen genomics, proteomics news

...for Rachitt with Genencor International (GCOR, Palo Alto, Calif.) and return GCOR's $550,000 licensing fee. Enchira Biotechnology Corp....
Read More
BioCentury | Aug 27, 2001
Finance

Ebb & Flow

...cap biotech company," said Leff. VIRS was up $0.73 (29%) on the week. Delisting quandary Enchira...
Read More
BioCentury | Jul 30, 2001
Company News

Enchira board of directors update

Enchira Biotechnology Corp. (ENBC), The Woodlands, Texas Business: Proteomics, High throughput screening Resigned: Nancy Chang and Tony Gorry WIR Staff...
Read More
BioCentury | Apr 2, 2001
Company News

Enchira other research news

...and the companies are awaiting the arbitrator's decision on a remedy (see BioCentury, March 12). Enchira Biotechnology Corp....
Read More
Items per page:
1 - 10 of 61
BioCentury | Jul 1, 2002
Finance

Cash watch

...$7.5 0.3 Genomic Solutions $25.1 $7.2 0.3 BioTime $3.3 $1.0 0.3 Heska $13.4 $4.2 0.3 Enchira...
Read More
BioCentury | May 13, 2002
Company News

Enchira genomics, proteomics news

...proteins that block cancer-related tyrosine kinase targets. The company said it is selling its assets. Enchira Biotechnology Corp....
Read More
BioCentury | Apr 15, 2002
Company News

Dyax, Enchira deal

...non-exclusively licensed its phage display technology to cancer company ENBC. Dyax Corp. (DYAX), Cambridge, Mass. Enchira Biotechnology Corp....
Read More
BioCentury | Jan 22, 2002
Company News

Enchira scientific advisory board update

Enchira Biotechnology Corp. (ENBC), The Woodlands, Texas Business: Genomics, Proteomics Appointed: John Smyth, professor of medical oncology at the University of Edinburgh; James Swartz, professor of chemical engineering at Stanford University; and Adrian Lee, assistant...
Read More
BioCentury | Dec 3, 2001
Clinical News

Template-based recombination methods regulatory update

...the patent covers the Rachitt technology, to which MAXY obtained exclusive ownership through arbitration with Enchira Biotechnology Corp....
Read More
BioCentury | Nov 19, 2001
Company News

Enchira scientific advisory board update

Enchira Biotechnology Corp. (ENBC), The Woodlands, Texas Business: Genomics, Proteomics Appointed: Lee Ellis, professor of surgical oncology and cancer biology at the University of Texas M.D. Anderson Cancer Center WIR Staff cancer...
Read More
BioCentury | Nov 12, 2001
Company News

Enchira, Maxygen genomics, proteomics news

...for Rachitt with Genencor International (GCOR, Palo Alto, Calif.) and return GCOR's $550,000 licensing fee. Enchira Biotechnology Corp....
Read More
BioCentury | Aug 27, 2001
Finance

Ebb & Flow

...cap biotech company," said Leff. VIRS was up $0.73 (29%) on the week. Delisting quandary Enchira...
Read More
BioCentury | Jul 30, 2001
Company News

Enchira board of directors update

Enchira Biotechnology Corp. (ENBC), The Woodlands, Texas Business: Proteomics, High throughput screening Resigned: Nancy Chang and Tony Gorry WIR Staff...
Read More
BioCentury | Apr 2, 2001
Company News

Enchira other research news

...and the companies are awaiting the arbitrator's decision on a remedy (see BioCentury, March 12). Enchira Biotechnology Corp....
Read More
Items per page:
1 - 10 of 61